DigestRedComo funciona
Red
/
Empresas
In
No verificado

Incyte

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

77 Comunicados de prensa

Ver todos los comunicados de prensa
02/12/2025
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
Fuente
Incyte
Editor
Business Wire
1.00
0
01/12/2025
Mercado laboral
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
Fuente
Incyte
Editor
Business Wire
1.00
0
19/11/2025
Eventos
Finanzas
Biotecnología
Farmacéutica
Salud
Incyte to Present at Upcoming Investor Conferences
Fuente
Incyte
Editor
Business Wire
1.00
0
17/11/2025
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)
Fuente
Incyte
Editor
Business Wire
1.00
0
06/11/2025
Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
Fuente
Incyte
Editor
Business Wire
1.00
0
03/11/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
Web y redes sociales
Telefonía
Eventos
Industria
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
Fuente
Incyte
Editor
Business Wire
1.00
0
30/10/2025
Oncología
Salud
Ciencia
Farmacéutica
Biotecnología
Eventos
Web y redes sociales
Incyte to Present at Upcoming Investor Conferences
Fuente
Incyte
Editor
Business Wire
1.00
0
28/10/2025
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Web y redes sociales
Telefonía
Mercado de valores
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
Fuente
Incyte
Editor
Business Wire
1.00
0
25/10/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Eventos
Industria
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
Fuente
Incyte
Editor
Business Wire
1.00
0
12/10/2025
Oncología
Salud
Ciencia
Farmacéutica
Biotecnología
Web y redes sociales
Eventos
Industria
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
Fuente
Incyte
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0